Coverage may be available if the medication is prescribed for type 2 diabetes
10 The 505(b)(2) pathway provides a regulatory route to overcome technical hurdles including stability, palatability, and manufacturing consistency, allowing firms to focus on improving drug performance rather than starting from zero. FDA 505(b)(2) Trend Analysis, 2025 14 The goal here is Defensive Innovation. By creating a differentiated productperhaps an oral liquid for patients with dysphagia or a longer-acting injectablea firm can bypass the innovators patents while offering a value story that payers will actually reimburse
Manage side effects proactively
In many cases, the tirzepatide alternatives listed below are effective at both
Herman R, Sikonja J, Jensterle M, Janez A, Dolzan V (2023) Insulin metabolism in polycystic ovary syndrome: secretion, signaling, and clearance
These are called ghrelin and leptin